Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 66.00 | |
5 mg | In stock | $ 162.00 | |
10 mg | In stock | $ 272.00 | |
25 mg | In stock | $ 490.00 | |
50 mg | In stock | $ 737.00 | |
100 mg | In stock | $ 987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 179.00 |
Description | BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases. |
Targets&IC50 | BTK:1 nM (IC50), BTK:0.3 nM (Kd) |
In vitro | BIIB068 inhibits B cell, neutrophil and monocyte activation in vitro, but not T cell responses. |
In vivo | BIIB068 demonstrated good PK/PD correlation with in vivo EC50 = 0.16 μM based on antibody esponse, similar to in vivo WB pBTK potency in mice. BIIB068 exhibited no adverse effects in the single dose CNS and respiratory studies in rats nor in a single dose cardiovascular study in monkeys. BIIB068 was well tolerated and effective at inhibiting BTK phosphorylation in healthy subjects. |
Molecular Weight | 435.52 |
Formula | C23H29N7O2 |
CAS No. | 1798787-27-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30mg/ml(68.88mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BIIB068 1798787-27-5 Angiogenesis Tyrosine Kinase/Adaptors BTK ADME inhibit FcγR Autoimmune Bruton tyrosine kinase TNFα BIIB 068 BIIB-068 ROS Inhibitor reversible Btk anti-IgD phosphorylation anti-IgM inhibitor